0
Relmada Therapeutics, Inc. Banner Image

Relmada Therapeutics, Inc.

  • Ticker RLMD
    Exchange NASDAQ More
  • Industry Drug Manufacturers - Other More
  • Sector Healthcare More
Relmada Therapeutics, Inc. Logo Image
  • 1-10 Employees
  • Based in New York City, New York
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, REL-1017 (dextromethadone) is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonistsMore may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
Relmada Therapeutics, Inc.

Most Recent Annual Report

Relmada Therapeutics, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Older/Archived Annual Reports